Researchers from The Second Qilu Hospital of Shandong University reported a microfluidic method that boosts CD19-targeting CAR-T cell transduction under low viral-dose conditions. The study targets one of the main bottlenecks in CAR-T manufacturing: the time- and resource-intensive steps required to achieve sufficient gene delivery. The team described a microfluidic approach intended to compress the core manufacturing timeline for CAR-T cells compared with conventional workflows. The focus on low viral doses also addresses practical scaling challenges linked to vector supply and cost. If the method translates beyond preclinical or early-stage validation, it could improve turnaround times for manufacturing and potentially broaden access by reducing the constraints associated with viral vector usage. For CAR-T developers, microfluidics represents a manufacturing-innovation lever distinct from clinical efficacy changes, with direct implications for operational throughput and batch consistency.